Cargando…

Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study

The mechanisms involved in the chronic hepatitis C progression are incompletely understood. The aim was to analyze the association between 2′5′oligoadenylate synthetase 1,2 and 3 (OAS1-3) and myxovirus resistance proteins 1 (Mx1) polymorphisms and severity of liver disease in human immunodeficiency...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Álvarez, Mónica, Berenguer, Juan, Jiménez-Sousa, María A., Pineda-Tenor, Daniel, Aldámiz-Echevarria, Teresa, Tejerina, Francisco, Diez, Cristina, Vázquez-Morón, Sonia, Resino, Salvador
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282518/ https://www.ncbi.nlm.nih.gov/pubmed/28139728 http://dx.doi.org/10.1038/srep41516

Ejemplares similares

FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients
por: Pineda-Tenor, Daniel, et al.
Publicado: (2014)

Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study
por: Guzmán-Fulgencio, María, et al.
Publicado: (2015)

Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome
por: Aldámiz-Echevarría, Teresa, et al.
Publicado: (2016)

ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2017)

PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study
por: García-Broncano, Pilar, et al.
Publicado: (2014)

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2016)

Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era
por: Alvaro-Meca, Alejandro, et al.
Publicado: (2017)

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis
por: Pineda-Tenor, Daniel, et al.
Publicado: (2015)

European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study
por: Aldámiz-Echevarría, Teresa, et al.
Publicado: (2019)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)
por: Vázquez-Morón, Sonia, et al.
Publicado: (2019)

Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer
por: Zhang, Yujie, et al.
Publicado: (2020)

Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
por: Pérez-Latorre, Leire, et al.
Publicado: (2018)

Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population
por: Hamano, Emi, et al.
Publicado: (2005)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
por: Vigón, Lorena, et al.
Publicado: (2019)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

On the silicon diodes, types OA 200 and OA 202
por: Mulder, P B
Publicado: (1958)

N2OAs 1
por: Frammery, B
Publicado: (1992)

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
por: Medrano, Luz Maria, et al.
Publicado: (2021)

Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study
por: He, Jing, et al.
Publicado: (2006)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
por: Brochado, Óscar, et al.
Publicado: (2021)

OAS1 and OAS3 negatively regulate the expression of chemokines and interferon-responsive genes in human macrophages
por: Lee, Wook-Bin, et al.
Publicado: (2019)

Vulnerabilities in WINCC OA
por: SEETARAMAN, Savita
Publicado: (2014)

Industry Perspective on OA
por: Margerrison, Ed. E. C.
Publicado: (2012)

N2OAS
por: Mulder, H
Publicado: (1996)

Making Sense of OA
por: Markovac, J., et al.
Publicado: (2015)

L-DOPA Is an Endogenous Ligand for OA1
por: Lopez, Vanessa M, et al.
Publicado: (2008)

Characteristics of Human OAS1 Isoform Proteins
por: Di, Han, et al.
Publicado: (2020)

Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status
por: Garcia-Broncano, Pilar, et al.
Publicado: (2018)

NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain
por: Jimenez-Sousa, María Ángeles, et al.
Publicado: (2016)

N2OAs 4
por: Frammery, B
Publicado: (1992)

N2OAs 5
por: Boillot, J, et al.
Publicado: (1992)

N2OAs 6
por: Cyvoct, G, et al.
Publicado: (1992)

n2oas 10
por: Boillot, J, et al.
Publicado: (1992)

N2OAs 12
por: Frammery, B, et al.
Publicado: (1992)

N2OAs 13
por: Frammery, B
Publicado: (1992)

N2OAs 2
por: Frammery, B
Publicado: (1992)

Mechanisms of Osteoarthritis (OA) Pain
por: O’Neill, Terence W., et al.
Publicado: (2018)

Initiating factors for the onset of OA: A systematic review of animal bone and cartilage pathology in OA
por: Casper‐Taylor, Michelle E., et al.
Publicado: (2020)

CD8(+) T Cells in OA Knee Joints Are Differentiated into Subsets Depending on OA Stage and Compartment
por: Platzer, Hadrian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qa5rcp48od8023vpcc72h4ar9u